Point-Of-Care Testing (POCT) Market Size, Share & Trends Analysis Report By Product (Blood Glucose Testing, Infectious Diseases Testing, Cardiac Markers Testing, Coagulation Testing, Pregnancy and Fertility Testing, Blood Gas/Electrolytes Testing, Urinalysis Testing, Others), By Applications (Clinics, Hospitals, Laboratory, Others), By End Use, By Region, and Segment Forecasts - 2035

Point-Of-Care Testing (POCT) Market Overview

The global point-of-care testing (poct) market size was valued at USD 33858.49 million in 2025 and is projected to grow from USD 37041.19 million in 2026 to USD 90962.65 million by 2035, at a CAGR of 9.4% from 2026 to 2035.

The global Point-Of-Care Testing (POCT) Market is experiencing substantial transformation as healthcare providers increasingly adopt rapid diagnostic technologies to improve clinical decision-making, reduce turnaround times, and expand access to medical testing. Point-of-care diagnostics allow healthcare professionals and appropriately trained users to perform tests at or near the patient, reducing dependence on centralized laboratory workflows for selected clinical decisions. The market includes Blood Glucose Testing, Infectious Diseases Testing, Cardiac Markers Testing, Coagulation Testing, Pregnancy and Fertility Testing, Blood Gas/Electrolytes Testing, Urinalysis Testing, and Others. North America represents an analytical 38% share of the defined market, supported by established healthcare infrastructure, regulatory pathways, and extensive utilization of decentralized diagnostic systems. Increasing diabetes prevalence, cardiovascular disease management requirements, and infectious disease surveillance are strengthening demand for portable diagnostic instruments. Manufacturers are integrating microfluidics, molecular amplification, biosensors, digital connectivity, and automated sample processing to improve analytical performance. Hospitals, clinics, laboratories, and decentralized healthcare providers are increasingly evaluating diagnostic solutions that support clinically appropriate results during the same patient encounter.

The United States Point-Of-Care Testing (POCT) Market remains an important center for diagnostic innovation, equipment commercialization, and decentralized healthcare delivery. American hospitals and clinics increasingly employ portable testing systems for glucose monitoring, rapid infectious disease screening, cardiac assessment, coagulation monitoring, and critical care diagnostics. The United States has approximately 40 million people living with diabetes, creating substantial requirements for ongoing glucose assessment and related medical services. Manufacturers including Abbott, Roche, Siemens Healthineers, Danaher, and LifeScan contribute diagnostic technologies used in different clinical environments. Regulatory clearances are expanding the availability of sophisticated molecular testing outside traditional laboratory settings. Roche obtained authorization for point-of-care molecular assays that can deliver selected infectious disease results in approximately 20 minutes. Healthcare organizations are also investing in electronic health record connectivity, quality assurance systems, and operator training. Continued demand for timely clinical information is encouraging healthcare providers to evaluate point-of-care instruments that combine analytical reliability, practical workflows, and appropriate regulatory authorization.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Blood Glucose Testing represents the largest product category with an analytical 29% market share, supported by widespread diabetes management requirements, regular monitoring practices, and established availability of portable diagnostic devices.
• Leading Application: Hospitals dominate the POCT application landscape with an analytical 43% share, reflecting extensive utilization of rapid diagnostics in emergency departments, critical care units, operating rooms, and bedside clinical assessment.
• Leading Region: North America leads the global POCT market with an analytical 38% share, supported by advanced healthcare infrastructure, substantial chronic disease testing requirements, and established diagnostic technology manufacturers.
• Fastest Growing Region: Asia-Pacific presents the strongest expansion potential, with a scenario-based 11% annual growth indicator supported by healthcare infrastructure development, decentralized testing programs, and increasing accessibility of diagnostic technologies.
• Technology Trend: High-sensitivity cardiac biomarker testing is advancing through compact analyzers, with bioMerieux's SPINCHIP platform providing selected cardiac troponin results in approximately 10 minutes using a small blood sample.
• Market Driver: Increasing chronic disease prevalence supports decentralized diagnostics, with approximately 589 million adults worldwide living with diabetes in 2024, reinforcing the importance of accessible blood glucose monitoring technologies.
• Competitive Landscape: Manufacturers are expanding rapid molecular diagnostic capabilities, demonstrated by Roche's 2025 regulatory clearance for selected multiplex infectious disease assays providing actionable results in approximately 20 minutes.
• Future Outlook: Connected testing, portable molecular diagnostics, and decentralized healthcare delivery are expected to support continued market development, with the supplied forecast indicating a 9.4% compound annual growth rate through 2035.

Latest Trends

The Point-Of-Care Testing (POCT) Market is witnessing increased adoption of rapid molecular diagnostics, connected monitoring systems, and compact devices designed for decentralized clinical environments. Healthcare providers are expanding the use of near-patient testing to support timely decisions during outpatient consultations, emergency assessments, and hospital admissions. Traditional antigen-based and biochemical tests remain important, while molecular platforms are introducing additional diagnostic capabilities through automated nucleic acid amplification. Roche's cobas liat technology demonstrates this development through multiplex assays capable of delivering selected infectious disease results in approximately 20 minutes. These systems can reduce delays associated with sample transportation and centralized laboratory processing, although appropriate confirmation and clinical interpretation remain essential. Manufacturers are developing cartridge-based devices with simplified sample preparation, intuitive user interfaces, and improved quality controls. Digital connectivity allows authorized personnel to transfer results into clinical information systems, supporting better documentation and patient follow-up. Healthcare organizations increasingly evaluate instruments according to test accuracy, regulatory status, operator requirements, total workflow time, and integration capabilities.

Innovation in high-sensitivity cardiac testing and chronic disease monitoring is creating additional opportunities for portable diagnostic technologies. BioMerieux introduced its SPINCHIP platform in September 2026, offering high-sensitivity cardiac troponin I testing through a compact instrument designed for near-patient use. The system requires a blood sample of approximately 14 microliters for its specified assay, demonstrating the growing importance of minimally invasive sample collection. Manufacturers are also improving glucose monitoring devices through connectivity, automated data transfer, smaller sample requirements, and enhanced usability. Infectious disease testing is moving toward multiplex panels capable of identifying multiple pathogens during a single testing procedure, improving diagnostic differentiation when symptoms overlap. Healthcare providers are simultaneously strengthening quality management because decentralized testing creates additional responsibilities for operator training, instrument maintenance, result verification, and clinical oversight. Digital platforms increasingly support device connectivity and remote monitoring, although cybersecurity, patient privacy, and interoperability requirements remain important implementation considerations.

Market Dynamics

Driver

""Increasing demand for rapid diagnosis and chronic disease monitoring accelerates POCT adoption.""

The increasing prevalence of chronic diseases and the growing requirement for timely diagnostic information are major drivers of the Point-Of-Care Testing Market. Diabetes management represents an important source of recurring testing demand because patients and healthcare professionals require glucose information to support appropriate treatment decisions. Approximately 589 million adults worldwide were living with diabetes in 2024, highlighting the scale of ongoing monitoring requirements. Portable blood glucose devices allow patients and clinicians to obtain measurements outside conventional laboratory environments, supporting routine management and assessment of selected acute conditions. Advances in device connectivity and automated result management are improving the accessibility of monitoring information. Manufacturers increasingly prioritize ease of use, appropriate analytical accuracy, and practical sample collection methods. The expansion of outpatient services and chronic disease management programs creates opportunities for diagnostic technologies that support timely testing and consistent patient monitoring.

Emergency and critical care requirements also strengthen demand for near-patient diagnostics. Hospitals increasingly utilize rapid tests to support cardiac assessment, metabolic monitoring, respiratory evaluation, and infectious disease management. Hospitals represent an analytical 43% of POCT applications, reflecting the importance of rapid clinical information in environments where treatment decisions may be time-sensitive. Portable instruments can reduce selected delays associated with laboratory transport and processing, although clinical benefits depend on appropriate workflows and test performance. Healthcare institutions increasingly evaluate total diagnostic turnaround time, including sample collection, instrument processing, result interpretation, and treatment decisions. Connected systems also help integrate test results with patient records and quality management processes. These developments are encouraging diagnostic manufacturers to introduce compact analyzers, automated cartridges, and reliable connectivity solutions for hospitals and other healthcare environments.

Restraint

""Quality assurance requirements and diagnostic accuracy concerns limit unrestricted deployment.""

Maintaining accurate and consistent test performance across decentralized healthcare environments remains a significant restraint affecting POCT implementation. Laboratory-based diagnostic services generally operate under established quality management procedures, while point-of-care systems may be used by professionals with varying levels of diagnostic training. Incorrect sample collection, improper storage, expired reagents, inadequate instrument maintenance, and operator errors can influence results. Blood Gas/Electrolytes Testing represents an analytical 10% of the defined market and requires careful attention to specimen handling because certain measured parameters can change rapidly after collection. Healthcare organizations must establish procedures covering instrument validation, internal quality control, external assessment, operator competency, and documentation. These requirements increase operational complexity and may limit adoption in facilities with insufficient staffing or technical infrastructure. Diagnostic manufacturers therefore emphasize automated quality checks, user guidance, and improved instrument interfaces to reduce avoidable errors.

Regulatory complexity and equipment costs create additional restraints. Point-of-care tests must meet applicable performance and authorization requirements, which may differ according to jurisdiction, intended use, specimen type, and testing environment. In the United States, CLIA-waived status can simplify deployment for eligible tests, but it does not remove the obligation to follow manufacturer instructions and maintain appropriate quality procedures. Certain molecular diagnostic instruments deliver results in approximately 20 minutes, yet their acquisition costs, cartridge expenses, and maintenance requirements may limit adoption in smaller facilities. Healthcare providers must evaluate whether faster results justify the resources needed for training, inventory management, connectivity, and technical support. In low-resource environments, dependable electricity, appropriate storage conditions, and secure data management can present additional barriers. Market expansion consequently depends on balancing analytical quality with affordability, usability, and practical operating requirements.

Opportunity

""Decentralized healthcare expansion creates opportunities for accessible diagnostic technologies.""

Increasing investment in decentralized healthcare services creates substantial opportunities for point-of-care diagnostic manufacturers. Rural clinics, community healthcare facilities, outpatient centers, and mobile medical services often require rapid testing methods that operate without extensive laboratory infrastructure. Asia-Pacific offers a scenario-based annual growth indicator of 11%, reflecting the potential importance of healthcare access initiatives and diagnostic equipment expansion. Manufacturers are developing compact instruments that require limited operator intervention while supporting reliable testing under appropriate conditions. Portable molecular systems can improve infectious disease screening where specimen transportation to centralized laboratories would otherwise delay evaluation. Blood glucose monitors, urinalysis devices, and rapid pregnancy tests also support accessible diagnostic services across different healthcare settings. Regional manufacturers are improving affordability and distribution, while established international companies are expanding technical partnerships. Successful deployment requires dependable supply chains, staff training, quality controls, and clear referral pathways for patients requiring additional evaluation.

Connected diagnostic devices and integrated digital healthcare platforms provide another important opportunity. Modern point-of-care instruments can transmit authorized results to electronic records, laboratory information systems, and remote clinical management platforms, reducing manual transcription requirements. The Clinics application segment represents an analytical 31% share of the defined market, demonstrating the commercial importance of outpatient diagnostic services. Medical practices increasingly seek instruments that support same-visit clinical assessment and minimize unnecessary follow-up appointments. Manufacturers are developing simplified cartridges, automated calibration systems, and secure connectivity functions to improve workflow integration. Advanced cardiac testing, respiratory infection screening, and glucose monitoring can strengthen clinical capabilities when supported by appropriate protocols. Healthcare providers also benefit from centralized oversight of decentralized testing programs, allowing quality managers to monitor instrument performance and operator competency across multiple locations. These developments support opportunities for equipment suppliers offering integrated diagnostic and information management capabilities.

Challenge

""Data interoperability and decentralized testing oversight complicate healthcare integration.""

Integrating diagnostic results from numerous point-of-care instruments into established healthcare information systems presents a significant operational challenge. Hospitals and clinics frequently use equipment from multiple manufacturers, creating differences in data formats, communication protocols, and result management procedures. Healthcare providers must ensure that patient identification, test timestamps, quality-control status, and analytical results are accurately documented. The Laboratory application segment accounts for an analytical 17% of the defined market, highlighting the continuing importance of laboratory professionals in managing decentralized diagnostic quality. Poor interoperability can increase administrative work and create risks associated with incomplete or duplicated records. Manufacturers increasingly develop standardized connectivity tools and middleware platforms to improve device integration. However, implementation requires cooperation among diagnostic suppliers, laboratory information technology teams, clinicians, and cybersecurity personnel. Effective oversight is essential for maintaining reliable clinical records and protecting sensitive patient information.

Variation in clinical performance and testing environments represents another challenge. Diagnostic accuracy depends on the intended use, specimen quality, disease prevalence, user technique, and analytical limitations of each device. Rapid molecular testing platforms may deliver results in approximately 20 minutes, but clinicians must still consider sensitivity, specificity, and the patient's clinical presentation when interpreting findings. False-positive and false-negative results can affect decisions when tests are used outside validated conditions. Manufacturers must provide clear instructions and appropriate performance evidence for different clinical applications. Healthcare facilities also need reliable reagent supplies, equipment maintenance procedures, and trained operators. Expanding into remote areas increases logistical complexity because temperature control, storage conditions, and replacement consumables may be difficult to maintain. Addressing these challenges requires coordinated regulatory compliance, quality management, practical training, and robust distribution infrastructure.

Segmentation Analysis

• 

  Download Free sample to learn more about this report.

By Types

Blood Glucose Testing: Blood Glucose Testing leads the POCT market with approximately 29% share within the analytical segmentation framework. The category includes portable glucose meters, test strips, and associated near-patient technologies used in diabetes management and selected acute care situations. Regular glucose assessment helps patients and healthcare professionals evaluate metabolic control and make informed treatment decisions according to established clinical guidance. Manufacturers including Roche, Abbott, LifeScan, Ascensia, ARKRAY, Sinocare, and Yuwell participate in the wider glucose monitoring ecosystem. Product development increasingly emphasizes convenient sample collection, compact devices, improved connectivity, and reliable analytical performance. Some systems require less than 1 microliter of capillary blood, depending on the specific device and test-strip design. Healthcare providers also value electronic documentation and the ability to review testing histories. Continued demand is supported by diabetes prevalence, outpatient care expansion, and increasing attention to patient self-management.

Infectious Diseases Testing: Infectious Diseases Testing accounts for approximately 21% of global POCT demand and supports rapid assessment of respiratory infections, selected sexually transmitted infections, and other clinically relevant pathogens. The category includes antigen-based assays, immunoassays, and compact molecular diagnostic technologies suited to authorized near-patient settings. Manufacturers are introducing multiplex platforms capable of detecting several infectious agents from a single specimen, improving diagnostic differentiation when clinical symptoms overlap. Roche's cobas liat system can provide selected molecular test results in approximately 20 minutes. These technologies support urgent care centers, hospitals, community clinics, and other decentralized healthcare facilities. Rapid testing may assist clinicians in making timely treatment and infection-control decisions when used according to appropriate protocols. Product innovation focuses on analytical sensitivity, simplified sample preparation, automated processing, and reliable performance in approved clinical environments.

Cardiac Markers Testing: Cardiac Markers Testing represents approximately 12% of the POCT market, reflecting demand for rapid assessment of patients with suspected cardiovascular emergencies. The category includes assays for cardiac troponin and other biomarkers used in appropriate diagnostic pathways. Portable analyzers can support emergency departments and acute care facilities where timely results influence patient assessment. BioMerieux introduced its SPINCHIP high-sensitivity cardiac troponin I platform in September 2026, demonstrating the progression of advanced biomarker testing toward decentralized settings. Its specified assay requires approximately 14 microliters of blood. Manufacturers are developing compact instruments and improved analytical technologies to support clinical performance comparable with applicable laboratory requirements. Cardiac marker results must be interpreted alongside patient symptoms, clinical history, electrocardiography, and relevant medical protocols. Demand is supported by the need for timely assessment and effective patient prioritization in emergency care.

Coagulation Testing: Coagulation Testing accounts for approximately 9% of the defined POCT market and supports the assessment of blood clotting parameters in selected clinical and patient-monitoring environments. Portable coagulation devices are used for applications such as international normalized ratio monitoring in patients receiving certain anticoagulant treatments. Rapid measurements can assist healthcare professionals in evaluating therapy and identifying results requiring additional clinical attention. Selected devices provide measurements within several minutes, improving convenience compared with workflows that require centralized laboratory processing. Manufacturers emphasize test-strip reliability, clear interfaces, automated quality checks, and practical specimen collection. Clinical adoption depends on accurate calibration, appropriate patient selection, and documented procedures for managing abnormal results. The category also includes testing requirements associated with surgical care and selected emergency situations. Continued development focuses on improving analytical consistency, operator usability, and connectivity with healthcare information systems.

Pregnancy and Fertility Testing: Pregnancy and Fertility Testing represents approximately 9% of POCT demand, supported by established use of rapid hormone-detection assays and growing interest in accessible reproductive health information. Pregnancy tests commonly detect human chorionic gonadotropin, while fertility-related devices may identify hormonal changes associated with ovulation. Many home pregnancy assays provide results within approximately 3 minutes, although timing and accuracy depend on the individual product and correct use. Manufacturers are developing digital interpretation features, simplified sampling procedures, and improved instructions to reduce user confusion. Healthcare facilities also employ point-of-care pregnancy testing to support clinical assessment and appropriate treatment planning. Consumer purchasing decisions are influenced by test reliability, convenience, privacy, and availability through retail channels. Product development increasingly emphasizes clear results, accessible instructions, and consistency across different testing environments.

Blood Gas/Electrolytes Testing: Blood Gas/Electrolytes Testing accounts for approximately 10% of the global POCT market and is particularly important in emergency departments, intensive care units, operating rooms, and other acute care environments. Portable systems can measure parameters associated with acid-base balance, blood gases, and electrolyte status, providing information relevant to immediate patient assessment. Abbott's i-STAT Alinity and Siemens Healthineers' epoc platform illustrate the importance of compact diagnostic systems for near-patient testing. Selected cartridges can deliver results in approximately 2 minutes after processing begins, depending on the instrument and assay. Clinical use requires correct specimen collection, careful handling, and appropriate interpretation because some blood gas parameters are sensitive to sampling conditions. Manufacturers emphasize automated quality monitoring, dependable cartridges, and simplified workflows. Demand is supported by the need for rapid critical care assessment and efficient clinical decision-making.

Urinalysis Testing: Urinalysis Testing represents approximately 6% of POCT demand and supports routine screening and assessment of selected urinary, renal, and metabolic conditions. Test strips can evaluate parameters such as glucose, protein, blood, ketones, and other indicators according to the specific assay. Many routine urine test strips require approximately 60 seconds for selected reagent reactions, although complete reading times vary between parameters and products. Portable readers improve standardization by reducing reliance on subjective visual interpretation. Clinics and hospitals use urinalysis in initial patient assessment, preventive screening, and follow-up investigations. Manufacturers are developing automated strip readers, digital documentation systems, and simplified sample-handling procedures. Clinical interpretation remains important because abnormal screening results may require confirmatory laboratory testing or further investigation. Demand is supported by relatively convenient testing procedures and broad applicability across healthcare settings.

Others: The Others category accounts for approximately 4% of the defined POCT market and includes specialized diagnostic applications not classified within the principal product categories. These may involve selected biochemical measurements, emergency assessment tools, and additional near-patient tests developed for specific clinical requirements. Manufacturers increasingly seek to miniaturize analytical technologies and integrate multiple measurements into compact instruments. Abbott's i-STAT traumatic brain injury testing technology illustrates specialized applications in which a bedside assay can support assessment of patients with suspected mild traumatic brain injury. The authorized whole-blood test can deliver results in approximately 15 minutes and must be used according to its specific indications. Advanced diagnostic development emphasizes meaningful clinical utility, manageable operating procedures, and appropriate regulatory approval. Continued innovation may expand the range of specialized tests available in decentralized healthcare environments.

By Applications

Clinics: Clinics account for approximately 31% of the global POCT market and represent an important environment for rapid outpatient assessment and decentralized medical services. Primary care centers, urgent care facilities, and specialist clinics increasingly use portable diagnostic devices to support consultations and minimize unnecessary delays. Point-of-care testing allows healthcare professionals to obtain selected results during a single patient encounter, supporting timely decisions when the test is clinically appropriate. Diagnostic applications include glucose monitoring, infectious disease screening, urinalysis, and selected cardiac or coagulation assessments. Modern molecular instruments can deliver results in approximately 20 minutes for specified assays, making them suitable for certain same-visit workflows. Clinics prioritize ease of operation, dependable reagent availability, manageable equipment maintenance, and electronic result documentation. Growing outpatient healthcare demand supports investment in diagnostic equipment that improves clinical accessibility while maintaining appropriate analytical quality.

Hospitals: Hospitals represent the leading application category with approximately 43% of global POCT market demand. Emergency departments, critical care units, surgical facilities, and inpatient wards require timely diagnostic information to support patient assessment and treatment decisions. Portable blood gas analyzers, glucose meters, coagulation systems, cardiac marker devices, and rapid infectious disease tests provide selected results near the patient. Some critical care assays deliver results within a few minutes, helping reduce delays associated with specimen transportation. Hospital adoption also depends on comprehensive quality assurance, operator competency, and integration with established laboratory information systems. Diagnostic suppliers increasingly provide centralized device management and connectivity tools to help institutions supervise large point-of-care testing networks. Continued pressure to improve patient throughput and clinical responsiveness supports investment in reliable near-patient diagnostic technologies.

Laboratory: Laboratory represents approximately 17% of global POCT applications and encompasses diagnostic departments managing satellite testing services, decentralized laboratory operations, and clinical oversight of near-patient devices. Laboratories play an important role in validating instruments, maintaining quality assurance procedures, managing operator training, and interpreting diagnostic performance. Many institutions oversee hundreds of point-of-care devices distributed across multiple departments, creating a need for coordinated data management and equipment monitoring. Laboratory professionals evaluate device accuracy, quality-control procedures, reference methods, and appropriate testing indications before authorizing clinical implementation. Connected platforms can improve oversight by consolidating instrument information and identifying potential quality problems. Laboratories also support outreach testing services and emergency diagnostic programs. Demand within this category reflects both direct testing activity and the expanding role of laboratory specialists in supervising decentralized healthcare diagnostics.

Others: The Others application segment represents approximately 9% of the defined POCT market and includes home testing, community outreach, mobile healthcare services, and additional decentralized environments outside the principal institutional categories. Portable diagnostic technologies can improve access for patients who experience barriers to conventional laboratory services. Home glucose testing is particularly established, while selected pregnancy and infectious disease assays are designed for authorized consumer use. Some home diagnostic products produce results within approximately 15 minutes, depending on their intended use and analytical method. Manufacturers emphasize clear instructions, accessible sample collection, and digital support to reduce avoidable errors. Community testing programs also require dependable supplies, appropriate storage conditions, and referral pathways for abnormal results. Opportunities are supported by healthcare accessibility initiatives and consumer interest in convenient health monitoring.

Regional Outlook

• 

  Download Free sampleto learn more about this report.

North America

North America leads the global Point-Of-Care Testing Market with an analytical 38% regional share, supported by advanced healthcare infrastructure, established diagnostic manufacturers, and extensive chronic disease management requirements. The United States is the principal regional market, with strong utilization of rapid diagnostic equipment in hospitals, clinics, emergency departments, and home healthcare environments. Companies including Abbott, Roche, LifeScan, Danaher, and Siemens Healthineers contribute technologies used across various testing categories. Demand reflects the need for timely glucose assessment, infectious disease screening, cardiac diagnostics, and critical care monitoring. Healthcare facilities increasingly prioritize connectivity, instrument reliability, and appropriate regulatory authorization. The region also benefits from established clinical research capabilities and significant investment in portable molecular testing. Increasing attention to decentralized healthcare delivery supports further development of integrated point-of-care services.

The United States continues introducing advanced diagnostic technologies through regulatory clearance and clinical implementation. Roche received authorization in January 2025 for selected cobas liat molecular assays designed to identify sexually transmitted infections, providing results in approximately 20 minutes. Abbott has also expanded bedside testing capabilities through its portable i-STAT instruments. Healthcare organizations increasingly evaluate diagnostic tools that support rapid decisions while maintaining appropriate clinical oversight. Canada contributes demand through hospital modernization, outpatient testing, and regional healthcare accessibility initiatives. Manufacturers continue strengthening electronic connectivity, quality management systems, and technical support to improve adoption. Regulatory requirements remain central to commercialization because diagnostic instruments must demonstrate suitable performance for their intended applications. North America's established healthcare infrastructure and technology development capabilities support its leading market position.

Europe

Europe accounts for approximately 26% of the global POCT market, supported by established public healthcare systems, advanced diagnostic infrastructure, and increasing demand for decentralized clinical assessment. Germany, France, the United Kingdom, Italy, and other European countries utilize near-patient testing across hospitals, primary care facilities, and selected community healthcare programs. Manufacturers including Roche, Siemens Healthineers, and BioMerieux maintain significant technology development and commercial activities within the region. Increasing attention to cardiovascular disease assessment, diabetes management, and infectious disease testing supports equipment adoption. European healthcare providers prioritize analytical quality, patient safety, and efficient diagnostic workflows. The In Vitro Diagnostic Regulation also influences product development, clinical evidence requirements, and market access. Demand increasingly favors devices that combine reliable testing performance with secure connectivity and manageable operating procedures.

European diagnostic innovation is expanding the availability of advanced point-of-care technologies. In September 2026, BioMerieux introduced the SPINCHIP high-sensitivity cardiac troponin I platform, designed to deliver results in approximately 10 minutes. The system targets clinical environments requiring rapid evaluation of suspected cardiac emergencies and supports the wider movement toward sophisticated near-patient diagnostics. Healthcare institutions are also investing in coordinated POCT management systems that improve instrument monitoring and operator oversight. Decentralized molecular testing can support appropriate respiratory and infectious disease assessment in locations where conventional laboratory workflows are less convenient. European manufacturers increasingly focus on assay performance, compact equipment design, and automated sample processing. Continued development will depend on regulatory compliance, healthcare purchasing priorities, and the demonstrated clinical value of rapid diagnostic results.

Asia-Pacific

Asia-Pacific represents approximately 24% of global POCT market demand and offers substantial opportunities through healthcare infrastructure expansion, population growth, and increasing requirements for accessible diagnostic services. China, India, Japan, South Korea, and Southeast Asian countries contribute different clinical and manufacturing conditions. Companies including ARKRAY, Sinocare, Wondfo, Yuwell, Runbio, Wuhan Easy Diagnosis, Getein Biotech, and Beijing Wantai BioPharm participate in regional diagnostic equipment and testing markets. Portable glucose monitoring and rapid infectious disease testing are important applications where local healthcare services require affordable and convenient technologies. Regional manufacturers are expanding product portfolios and improving manufacturing capabilities to support different healthcare settings. The growing importance of outpatient care and rural health programs creates demand for compact analyzers, portable test kits, and dependable reagent distribution.

Asia-Pacific is positioned as the fastest-growing region within the analytical framework, with a scenario-based annual growth indicator of 11%. Expansion potential reflects increased healthcare investment, broader diagnostic awareness, and efforts to improve access outside major urban medical centers. Manufacturers are developing portable instruments suitable for community clinics, mobile healthcare facilities, and smaller hospitals. China maintains substantial diagnostic manufacturing capacity, while India represents an important opportunity for scalable testing solutions. Japan and South Korea contribute advanced medical technology development and established clinical quality requirements. Local market expansion depends on affordability, regulatory approval, healthcare reimbursement, and access to trained operators. Digital connectivity and simplified sample processing can further improve practical adoption. Suppliers offering dependable technical support and competitively positioned diagnostic products may benefit from the region's long-term healthcare development.

Latin America

Latin America represents approximately 7% of the global Point-Of-Care Testing Market, supported by increasing healthcare access initiatives and demand for affordable diagnostic technologies. Brazil, Mexico, Argentina, and other countries offer opportunities for point-of-care testing across hospitals, clinics, and community healthcare services. Regional demand is influenced by diabetes management requirements, infectious disease screening, maternal health services, and efforts to improve diagnostic accessibility. Portable testing devices may be particularly useful in locations where specimen transportation to centralized laboratories creates delays. Healthcare facilities increasingly evaluate compact glucose monitors, rapid antigen tests, urinalysis devices, and other authorized near-patient technologies. Equipment affordability, reliable distribution, and appropriate operator training remain important purchasing considerations. Manufacturers can improve adoption through local partnerships and accessible technical assistance.

Regional market development is closely linked to strengthening primary healthcare capabilities and improving diagnostic supply chains. Clinics represent an analytical 31% of global POCT applications, illustrating the broader opportunity for outpatient testing models that can support Latin American healthcare facilities. Community health programs may benefit from portable diagnostic equipment when supported by quality controls and clear clinical referral procedures. Manufacturers are also developing user-friendly devices that reduce complex sample preparation and support reliable performance under varied operating conditions. Digital healthcare expansion creates opportunities for test-result documentation and remote clinical collaboration. However, procurement budgets, regulatory requirements, and uneven infrastructure can influence equipment deployment. Long-term growth depends on healthcare investment, dependable consumable supplies, and the availability of training and quality assurance services.

Middle East and Africa

The Middle East and Africa account for approximately 5% of the global POCT market, reflecting varied healthcare infrastructure and substantial opportunities to improve diagnostic accessibility. Countries across the Gulf region are investing in modern hospitals and healthcare services, while several African markets prioritize affordable diagnostics for infectious disease detection and chronic illness management. Portable testing equipment can support healthcare delivery where centralized laboratories are difficult to access. Demand is influenced by diabetes prevalence, maternal healthcare requirements, infectious disease surveillance, and emergency diagnostic needs. Manufacturers must consider equipment durability, reagent storage, operator training, and access to maintenance services. Healthcare systems increasingly evaluate point-of-care technologies that can operate reliably with limited laboratory infrastructure. International diagnostic suppliers and regional distributors contribute to product availability and technical support.

Expanding community healthcare programs and diagnostic outreach initiatives create opportunities for further market development. Some rapid infectious disease tests can provide results in approximately 15 minutes, supporting timely assessment in appropriately equipped decentralized settings. Portable glucose meters and pregnancy tests also provide practical diagnostic capabilities for facilities with limited laboratory resources. Regional demand varies considerably according to purchasing power, medical infrastructure, and regulatory conditions. In selected African markets, dependable test distribution and appropriate storage remain important challenges. Gulf healthcare providers increasingly emphasize connected diagnostic systems and advanced hospital technology. Manufacturers offering robust equipment, clear user instructions, and suitable quality controls are positioned to support wider adoption. Long-term development will depend on coordinated healthcare investment and practical access to diagnostic services.

List of Top Point-Of-Care Testing (POCT) Companies

• Roche
• Abbott
• LifeScan
• Siemens Healthineers
• Danaher
• Ascensia
• BioMerieux
• ARKRAY
• Sinocare
• Wondfo
• Yuwell
• Runbio
• KHB
• Wuhan Easy Diagnosis
• J.H.Bio-Tec
• Getein Biotech
• ReLIA
• BIOUHAN
• Beijing Wantai BioPharm
• Hotgen
• Intec PRODUCT
• Shenzhen YHLO
• Kang Hua

Top 2 Companies with Highest Market Share

• Abbott: Abbott maintains a leading competitive position within the global point-of-care diagnostics industry through its extensive portable testing technologies and established healthcare relationships. Its i-STAT platforms support selected critical care and specialized bedside diagnostic applications, while the company's wider diagnostics capabilities contribute to decentralized healthcare services. The i-STAT TBI cartridge received authorization for whole-blood use in April 2024, enabling results in approximately 15 minutes for its specified clinical application. Abbott's competitive strengths include portable instrument engineering, established distribution networks, regulatory experience, and technical customer support. An independently verified global POCT market share for the company is not available under a consistent product definition, so a numerical ranking cannot be established reliably.
• Roche: Roche is another major participant in the global POCT industry, supported by established diagnostic technologies, international distribution capabilities, and ongoing molecular testing innovation. Its cobas liat system offers rapid molecular testing for selected infectious diseases, including assays that provide results in approximately 20 minutes. Roche also participates in glucose monitoring and broader diagnostic technology markets. The company's strengths include automated assay development, clinical performance evaluation, regulatory expertise, and relationships with healthcare providers. Continued investment in multiplex testing supports expansion into appropriate decentralized clinical environments. Its precise global POCT market share cannot be independently verified from consistently defined public figures, although its product breadth and diagnostic development activities demonstrate substantial competitive influence.

Investment Analysis and Opportunities

Investment activity in the POCT market increasingly focuses on rapid molecular diagnostics, connected monitoring devices, compact analyzers, and decentralized healthcare infrastructure. Hospitals and clinics are evaluating technologies that improve diagnostic turnaround times while maintaining appropriate analytical quality and regulatory compliance. Hospitals account for an analytical 43% of global POCT applications, making institutional adoption an important consideration for diagnostic manufacturers and technology investors. Product development opportunities include automated sample processing, cartridge-based testing, high-sensitivity biosensors, and secure integration with healthcare information systems. Investments in operator training, quality management software, and instrument connectivity can strengthen commercial adoption by reducing implementation complexity. Manufacturers are also expanding reagent production and distribution capabilities to support dependable test availability. Successful investment strategies require consideration of clinical performance, reimbursement arrangements, regulatory pathways, and long-term customer service requirements.

Emerging healthcare markets and specialized diagnostic applications offer further investment opportunities. Asia-Pacific's scenario-based annual growth potential of 11% reflects opportunities associated with improving healthcare access and expanding local diagnostic manufacturing. Manufacturers are developing affordable instruments that provide dependable results with limited sample preparation and manageable operating requirements. High-sensitivity cardiac testing, portable infectious disease screening, and integrated glucose monitoring represent important areas for continued technical development. Digital connectivity offers additional opportunities through device management platforms, automated quality oversight, and secure transmission of diagnostic information. Investors must also consider the recurring need for assay cartridges, reagent supplies, calibration materials, and maintenance services. Long-term opportunities are strongest where advanced technology addresses a clearly defined clinical requirement and can be implemented through sustainable healthcare workflows.

New Product Development

New product development in the Point-Of-Care Testing Market increasingly emphasizes rapid molecular diagnostics, automated sample processing, and compact instruments capable of delivering clinically useful results near patients. Manufacturers are introducing multifunctional testing platforms that support improved workflow efficiency while reducing complicated preparation procedures. Roche expanded its cobas liat diagnostic capabilities through additional infectious disease assays, including multiplex tests authorized for decentralized clinical use. The company's selected molecular tests provide results in approximately 20 minutes, demonstrating the increasing accessibility of advanced nucleic acid amplification technology. Abbott has developed additional applications for its portable i-STAT systems, including whole-blood traumatic brain injury assessment designed to support clinical decision-making under authorized conditions. Manufacturers are also improving cartridge handling, quality-control functions, and electronic connectivity. These developments reflect an emphasis on reliable diagnostic performance and practical integration into hospitals, clinics, and other approved healthcare environments. Product differentiation increasingly depends on regulatory authorization, clinical utility, sample requirements, and the ability to provide useful information within appropriate treatment pathways.

High-sensitivity cardiac diagnostics and multiplex infectious disease detection are becoming increasingly important areas of POCT innovation. BioMerieux launched its SPINCHIP platform in September 2026, introducing a high-sensitivity cardiac troponin I assay designed for rapid evaluation of suspected acute cardiac events. The instrument uses approximately 14 microliters of blood for its specified test, demonstrating progress in compact analytical platforms and low-volume specimen collection. In October 2026, BioMerieux also announced regulatory clearance and a CLIA waiver for its BIOFIRE SPOTFIRE Vaginitis Panel, expanding the availability of automated molecular testing in appropriate decentralized settings. Manufacturers are integrating sample preparation, reagent management, and analytical processing into simplified cartridges to reduce operator complexity. Digital connectivity allows healthcare organizations to improve documentation and instrument oversight. Continued product development focuses on analytical reliability, accessible interfaces, shorter testing workflows, and technologies capable of meeting clinical requirements outside conventional laboratory environments.

Five Recent Developments

• April 2024 – Abbott Expanded Bedside Brain Injury Testing: Abbott received United States FDA clearance for the use of whole blood with its i-STAT TBI cartridge on the portable i-STAT Alinity instrument. The test provides results in approximately 15 minutes and supports the assessment of eligible patients with suspected mild traumatic brain injury. The development expanded bedside diagnostic capabilities by reducing the need for separate laboratory sample preparation.
• June 2024 – Roche Advanced Multiplex Respiratory Disease Diagnostics: Roche received FDA emergency use authorization for its cobas liat molecular assay designed to detect and differentiate SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus. The assay identifies 4 respiratory viral targets through a single testing procedure and provides results in approximately 20 minutes. The development strengthened near-patient molecular diagnostic capabilities for respiratory disease assessment.
• January 2025 – Roche Expanded Rapid Sexually Transmitted Infection Testing: Roche announced FDA clearance and a CLIA waiver for its cobas liat sexually transmitted infection multiplex assay panels. The tests support rapid molecular detection of selected infections in appropriately authorized decentralized environments. Results are available in approximately 20 minutes, providing clinicians with information that can support same-visit treatment decisions when combined with suitable clinical evaluation.
• September 2026 – BioMerieux Introduced High-Sensitivity Cardiac Testing Platform: BioMerieux launched SPINCHIP, a compact point-of-care diagnostic platform featuring its high-sensitivity cardiac troponin I assay. The system was introduced for initial availability in Europe and designed to support emergency assessment of patients with suspected cardiac events. The specified test requires approximately 14 microliters of blood and provides results in around 10 minutes.
• October 2026 – BioMerieux Received Clearance for Vaginitis Testing: BioMerieux announced FDA clearance and a CLIA waiver for its BIOFIRE SPOTFIRE Vaginitis Panel on October 22, 2026. The automated multiplex molecular assay identifies common causes of vaginitis through a single testing process. Results are available in approximately 20 minutes, expanding diagnostic options for authorized near-patient healthcare settings and supporting more timely clinical evaluation.

Report Coverage

The Point-Of-Care Testing (POCT) Market Report provides a comprehensive examination of diagnostic technologies, product segmentation, healthcare applications, regional development, competitive positioning, and emerging opportunities. The analysis evaluates Blood Glucose Testing, Infectious Diseases Testing, Cardiac Markers Testing, Coagulation Testing, Pregnancy and Fertility Testing, Blood Gas/Electrolytes Testing, Urinalysis Testing, and Others. Blood Glucose Testing represents an analytical 29% share of the defined market, reflecting the substantial role of chronic disease monitoring in decentralized diagnostics. Application coverage includes Clinics, Hospitals, Laboratory, and Others, examining differences in clinical requirements, equipment adoption, and quality assurance responsibilities. The competitive assessment covers Roche, Abbott, LifeScan, Siemens Healthineers, Danaher, Ascensia, BioMerieux, ARKRAY, Sinocare, Wondfo, Yuwell, Runbio, KHB, Wuhan Easy Diagnosis, J.H.Bio-Tec, Getein Biotech, ReLIA, BIOUHAN, Beijing Wantai BioPharm, Hotgen, Intec PRODUCT, Shenzhen YHLO, and Kang Hua. The report considers product portfolios, technology development, regulatory progress, distribution capabilities, and decentralized healthcare adoption.

The geographical assessment covers North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa, examining healthcare infrastructure, diagnostic accessibility, regional manufacturing capabilities, and regulatory requirements. North America holds an analytical 38% share of the defined global POCT market, supported by advanced healthcare systems and established diagnostic technologies. The report evaluates growth drivers including chronic disease management, rapid infectious disease detection, and increasing demand for timely clinical information. It also considers challenges associated with analytical accuracy, quality management, regulatory authorization, instrument maintenance, and healthcare data integration. Investment coverage addresses molecular diagnostic platforms, portable biosensors, automated sample processing, connected instruments, and expansion into underserved healthcare environments. Recent developments from 2024 through October 2026 highlight regulatory clearances and product launches involving rapid molecular testing and specialized bedside diagnostics. The forecast assessment extends through 2035 and evaluates the influence of clinical innovation, healthcare decentralization, digital connectivity, and evolving diagnostic requirements on industry development.